Benzinga | Aug 19, 2020 09:09AM EDT

Hoth Therapeutics Provides Shareholder Update

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company,today is providing shareholders with a update on its COVID-19 initiatives including vaccine and real-time, breath-based mobile testing deviceas well as its dermatological therapy pipeline.

Mr.Robb Knie, Chief Executive Officer of Hoth, commented,"By leveraging our platform, expertise and strategic relationships, we have made significant progress in advancing our robust therapeutics pipeline.Additionally, we've been able to invest in strategic, undervalued assets -- all amidst the ongoing global pandemic.Since inception, we have acquired the rights to assets that addresses global issues, via our partnership for a COVID-19 vaccine, novel peptides and medical device. While continuing to evaluate these assets, we recently submitted for ethics board approval in Australiafor our lead therapy candidate, BioLexa, for Atopic Dermatitis, to launch our clinical study in humans during the second half of this year. Going forward, we have several initiatives that we believe will help enhance shareholder value."